How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapsed-or-refractory-pediatric-low-grade-glioma-lgg-harboring-a-braf-v600-mutation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Ojemda	TOVORAFENIB	Day One Biopharms	Kinase Inhibitor [EPC]			2024-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-20 — Ojemda · EMA · approved · EU

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Day One Biopharms · 1 drug in relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation:

Cite this brief

Drug Landscape (2026). relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsed-or-refractory-pediatric-low-grade-glioma-lgg-harboring-a-braf-v600-mutation. Accessed 2026-06-10.

relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing